Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Survey of oncologists finds knowledge gap on medical marijuana

As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers. Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial…
Read More →

New Feature Updates

It’s a new feature alert! At Arfinn Med we always work to make sure we are the industry leading software platform and EMR for medical cannabis providers and clinics. Keeping with that sentiment, we’ve recently updated two features that have been very popular with Arfinn Med users.  Those are the customizable consent and confirmation page…
Read More →

LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY

There are less opioid prescriptions on average in U.S. states where medical and recreational marijuana are legal, research has revealed. Access to recreational cannabis in the U.S. was tied with a 11.8 percent lower rate of opioids prescriptions each day, and 4.2 percent for medical marijuana. The authors of the paper published in the Journal of Health Economics said recreational weed…
Read More →

July Updates

In our quest to save medical marijuana clinics valuable time, Arfinn Med has continued to release new functionality that improves EMR workflows.  This has led to the development of our new telehealth platform, new automated patient intake emails, and generating all state required documentation.  Continuing on our quest, we are proud to release our new…
Read More →

A Message To Our Clients

To Our Clients, First of all, I hope everyone is staying safe and healthy in these unprecedented times.  I want to assure you that Arfinn Med has systems in place to ensure that our workflows are not impacted from having staff work remotely and we will continue to provide the same quality product and customer service…
Read More →

Are You Prepared For Questions About Medical Cannabis?

With over 85% of Americans supporting legalizing medical cannabis, it’s inevitable that patients will begin asking their primary care doctors about its use and overall efficacy. Doctors and other medical professionals will be called upon to be ‘sense-makers’ for a treatment they never studied in medical school and have limited available research to draw upon. …
Read More →

Leave a Comment

You must be logged in to post a comment.